Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization

Journal Title: International Journal of Ophthalmology - Year 2019, Vol 12, Issue 3

Abstract

"AIM: To investigate the incidence of abrupt visual loss and its associated factors, during anti-vascular endothelial growth factor (VEGF) treatment for type 3 neovascularization. METHODS: This retrospective study included 137 eyes that were newly diagnosed with type 3 neovascularization. All eyes were treated with anti-VEGF therapy. Abrupt visual loss was defined as loss of 5 or more lines in best-corrected visual acuity (BCVA) in comparison to the previous visit. The incidence and timing of abrupt visual loss as well as the factors associated with it, were determined. In addition, the BCVA at the final follow-up was compared between the eyes with and those without abrupt visual loss. RESULTS: The mean follow-up period was 42.4±18.9mo after diagnosis, and abrupt visual loss was noted in 22 eyes (16.1%) at a mean of 19.6±13.9mo. Abrupt visual loss was found to be associated with subretinal hemorrhage in 11 eyes (50.0%), development of or increase in the height of pigment epithelial detachment with fluid in 8 eyes (36.4%), and tears in the retinal pigment epithelium in 3 eyes (13.6%). The logarithm of minimum angle of resolution (logMAR) mean BCVA at the final follow-up was 2.07±0.67 (Snellen equivalents: 20/2349) and 1.00±0.55 (20/200) in eyes with and without abrupt visual loss, respectively. BCVA was significantly worse in the eyes with abrupt visual loss (P<0.001). CONCLUSION: Abrupt visual loss is noted in 16.1% of patients with type 3 neovascularization and is associated with poor visual outcome. Additional studies are needed to determine how abrupt visual loss can be prevented."

Authors and Affiliations

Jae Hui Kim

Keywords

Related Articles

Quality of life in glaucoma patients after selective laser trabeculoplasty

"AIM: To compare quality of life and treatment satisfaction between patients who had selective laser trabeculoplasty (SLT) and those on medication. METHODS: A prospective clinical trial on 143 glaucoma patients that rece...

Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment in vitro

"AIM: To investigate the mechanism underlying the loss of responsiveness to anti-vascular endothelial growth factor (VEGF) treatment after repeated injections for choroidal neovascularization, VEGF and VEGF receptor (VEG...

Effect of intracorneal ring segment implantation on corneal asphericity

"AIM: To evaluate the visual, refractive and corneal asphericity changes after intrastromal corneal ring segment (ICRS) implantation for visual rehabilitation of keratoconus. METHODS: A total of 42 eyes of 32 patients we...

Predictive factors for photic phenomena after refractive, rotationally asymmetric, multifocal intraocular lens implantation

"AIM: To investigate the independent factors associated with photic phenomena in patients implanted with refractive, rotationally asymmetric, multifocal intraocular lenses (MIOLs). METHODS: Thirty-four eyes of 34 patient...

Download PDF file
  • EP ID EP591506
  • DOI 10.18240/ijo.2019.03.20
  • Views 36
  • Downloads 0

How To Cite

Jae Hui Kim (2019). Abrupt visual loss during anti-vascular endothelial growth factor treatment for type 3 neovascularization. International Journal of Ophthalmology, 12(3), -. https://europub.co.uk/articles/-A-591506